Tarian Pharma is a biopharmaceutical company focused on developing investigational topical drug candidates for oncology supportive care. The company is developing new approaches to address selected cancer treatment related skin toxicities that can lead to dose reductions or interruptions or cancer treatment cessation and affect patients’ quality of life. Tarian Pharma’s lead program, TAR-0520, is an investigational topical brimonidine gel being developed for several oncology supportive care indications. Tarian Pharma is a biopharmaceutical company developing investigational topical drug candidates for oncology supportive care. Its lead program, TAR-0520, is a topical brimonidine gel being studied to help prevent selected cancer treatment (EGFR inhibitor-induced folliculitis, chemotherapy-induced peripheral neuropathy, and hand-foot syndrome) related skin toxicities, that can lead to dose reductions or interruptions or cancer treatment cessation and affect patients’ quality of life. The goal is to reduce the local impact of anticancer treatments on peripheral tissues while supporting patients’ quality of life and continuity of cancer treatment. TAR-0520 remains investigational and is not approved for commercial use.
Tarian Pharma’s mission is to develop new therapeutic approaches in oncology supportive care to help prevent skin toxicities associated with cancer treatments. These cancer treatment-related skin toxicities include side effects that cause pain, discomfort, functional limitations, stigma and psychological burden. In severe cases, they can contribute to cancer treatment dose reduction, treatment modification or discontinuation. Tarian Pharma focuses on developing topical therapies designed to act locally and integrate into existing oncology treatment protocols, with the objective of supporting patients throughout their cancer therapy.
Tarian means “shield” in Welsh. The name reflects Tarian Pharma’s ambition to protect patients from selected toxicities associated with cancer treatment while supporting continuity of care. This concept is central to the company’s oncology supportive care strategy and to TAR-0520, its investigational topical brimonidine gel. The name also acknowledges the Welsh heritage of one of the company’s founders: Gareth Winckle.
Oncology supportive care (also defined as cancer supportive care) includes treatments and interventions that help prevent, reduce, or manage side effects and complications caused by cancer and anticancer therapies. It can address treatment-related toxicities, pain, functional limitations, psychological burden, and quality of life throughout the cancer treatment pathway. Tarian Pharma focuses on preventive oncology supportive care, with investigational topical approaches for selected cancer treatment-related skin toxicities where additional preventive options are needed.
TAR-0520 is Tarian Pharma’s investigational topical brimonidine gel for oncology supportive care. It contains brimonidine tartrate, an alpha-2 adrenergic agonist with vasoconstrictive properties. TAR-0520 is being studied as a preventive approach for selected cancer treatment-related toxicities, including EGFR inhibitor-induced folliculitis, chemotherapy-induced peripheral neuropathy, and hand-foot syndrome. The product is under clinical investigation and is not approved for commercial use in any jurisdiction.
Brimonidine tartrate is an alpha-2 adrenergic agonist with vasoconstrictive properties, meaning it can narrow blood vessels and reduce local blood flow. It is the active pharmaceutical ingredient in TAR-0520, Tarian Pharma’s investigational topical gel. In the TAR-0520 oncology supportive care program, local vasoconstriction is being investigated to reduce exposure of selected peripheral tissues to circulating anticancer treatments and inflammatory cells. TAR-0520 remains investigational.
TAR-0520 is designed to induce local vasoconstriction following topical application. Its active ingredient, brimonidine tartrate, is an alpha-2 adrenergic agonist with vasoconstrictive activity on skin capillaries. By reducing local blood flow, TAR-0520 is being investigated for its potential to decrease peripheral blood flow in small vessels and thus reduce local tissue exposure to circulating anticancer treatments and inflammatory cells. This pharmacological approach is designed to mimic the protective mechanism demonstrated by peripheral cooling devices (cooling caps, socks and gloves). TAR-0520 remains investigational, and its clinical safety and efficacy are still under evaluation.
TAR-0520 is formulated as a topical brimonidine gel so it can be applied directly to the area where a local effect is sought. The topical route is designed to produce local vasoconstriction while limiting systemic exposure to brimonidine. Phase 1 studies conducted by Tarian Pharma involved 62 healthy volunteers and evaluated local and systemic tolerability, pharmacokinetics, and vasoconstrictive activity. Excellent local and systemic tolerance were demonstrated. The topical format is also intended to support an application schedule adapted to different oncology treatment protocols. TAR-0520 remains investigational.
TAR-0520 gel is applied to the areas of skin most prone to the relevant to each toxicity being studied. For patients receiving EGFR inhibitor therapy, this typically means the face, upper chest, and back, the areas most affected by EGFRi-associated folliculitis. For patients receiving taxane chemotherapy, the gel is applied to the hands and feet to help prevent chemotherapy-induced peripheral neuropathy (CIPN). For patients receiving chemotherapy agents associated with hand-foot syndrome (HFS), the gel is applied to the palms and soles, the primary sites affected by this toxicity. TAR-0520 is designed for ease of use: patients can self-administer, or a family member or carer can assist. TAR-0520 remains investigational and is not approved for routine clinical use.
The TAR-0520 application schedule depends on the anticancer treatment and the clinical study protocol. In the current development program, the gel is applied before treatment and then once daily for a duration designed to match the persistence of the relevant anticancer drug in plasma. The program includes schedules of three days for taxane-based regimens and seven days for EGFR inhibitor therapy. TAR-0520 remains investigational, so these schedules should not be interpreted as approved prescribing instructions.
Tarian Pharma is developing TAR-0520 for selected cancer treatment-related toxicities with a significant impact on patient comfort, function, quality of life, and cancer treatment delivery. Current Phase 2 proof-of-concept development includes EGFR inhibitor-induced folliculitis, chemotherapy-induced peripheral neuropathy, also called CIPN, and capecitabine-induced hand-foot syndrome, or HFS. Chemotherapy-induced alopecia is also part of the broader development strategy, with additional formulation work required before Phase 2a readiness.
EGFR inhibitor-induced folliculitis is a dermatologic toxicity associated with anticancer therapies that target the epidermal growth factor receptor, or EGFR. It typically appears as an acneiform or papulopustular rash and can involve redness, inflammation, itching, tenderness, discomfort, and pain. More severe cases can affect quality of life and cancer treatment delivery. Tarian Pharma is evaluating TAR-0520 topical brimonidine gel as an investigational preventive approach for EGFR inhibitor-induced folliculitis.
Hand-foot syndrome, also known as palmar-plantar erythrodysesthesia, is a treatment-related toxicity associated with certain anticancer therapies, including capecitabine. It mainly affects the palms of the hands and soles of the feet and can cause redness, swelling, tenderness, burning, and pain. Symptoms can interfere with walking, gripping objects, and everyday activities, and severe cases can lead to changes in cancer treatment. Tarian Pharma is studying TAR-0520 as an investigational preventive approach for capecitabine-induced hand-foot syndrome.
Chemotherapy-induced peripheral neuropathy, or CIPN, is a peripheral nerve toxicity caused by certain chemotherapy treatments, including taxanes. It commonly affects the hands and feet and can cause numbness, tingling, pain, and reduced sensitivity. CIPN can interfere with walking, dexterity, and everyday activities. In some patients, severe chemotherapy induced peripheral neuropathy can become dose-limiting and affect cancer treatment delivery. Tarian Pharma is evaluating TAR-0520 topical brimonidine gel as an investigational preventive approach for CIPN.
Chemotherapy-induced alopecia is hair loss caused by certain chemotherapy treatments, including taxanes. Depending on the regimen, hair loss can affect the scalp and other areas of the body and can create a significant emotional, psychological, and social burden for patients. Tarian Pharma includes chemotherapy-induced alopecia within its broader oncology supportive care development strategy. Additional formulation work is required before the TAR-0520 program is ready for Phase 2a development in this indication.
TAR-0520 is currently in clinical development across several oncology supportive care indications. Tarian Pharma has completed Phase 1 studies in 62 healthy volunteers, evaluating local and systemic tolerability, pharmacokinetics, and vasoconstrictive activity. Phase 2 proof-of-concept studies are now underway for three indications: prevention of EGFR inhibitor-associated folliculitis, prevention of chemotherapy-induced peripheral neuropathy (CIPN), and prevention of capecitabine-induced hand-foot syndrome (HFS). TAR-0520 remains investigational and is not approved for commercial use in any jurisdiction.
No. TAR-0520 is an investigational topical brimonidine gel and is not commercially available or approved for routine clinical use. Tarian Pharma is evaluating TAR-0520 in clinical studies for selected oncology supportive care indications, including EGFR inhibitor-induced folliculitis, chemotherapy-induced peripheral neuropathy, and hand-foot syndrome . Its safety and efficacy remain under clinical evaluation. Any future availability would depend on successful clinical development and applicable regulatory review and approval.
Scientific information about TAR-0520 is available through Tarian Pharma’s scientific and clinical materials, including study updates, scientific posters, conference presentations, publications, and information about the mechanism of action of topical brimonidine. These resources describe the company’s oncology supportive care program, clinical development status, and selected milestones. For the latest materials, visitors should use the scientific resources and news sections of the Tarian Pharma website or contact the company directly.
Pharmaceutical and biotechnology companies, investors, and other strategic partners interested in TAR-0520 can contact Tarian Pharma through the company’s contact page. The company is considering partnership structures including regional or global licensing, co-development, strategic investment, and option-to-license arrangements related to future development and potential commercialization. Partnership discussions concern investigational programs that remain subject to clinical development and regulatory review.
